Dr Ashish Kumar

I am proud to share that for the FIFTH consecutive year, my name has appeared in the list of the world’s top 2% scientists (published in September 2025 by researchers from Stanford University, USA). From India, I am ranked 25th in the field of Gastroenterology and Hepatology.

Metformin first… or is that outdated now?

Phase II results #chiglitazar, a PPAR pan-agonist, reduced liver fat by 24.9% (48mg) & 36.3% (64mg) vs placebo in MASLD pts w/ hyperTG & IR over 18wks. Improved ALT/AST, lipids, well-tolerated. journals.lww.com/hep/fulltext/2…

🇮🇳 Real-world data from >1000 patients with MASLD/MetALD MRI-PDFF phenotyping + 🧲 MRE anchor 🔍 Key takeaways: ✔️ Similar CMRF & AF burden ✔️ FIB-4 & NFS perform well ❌ APRI underperforms 💡 Simple NITs even for MetALD @AnandVKulkarni2 @DrMaheshgoenka link.springer.com/article/10.118…

Some exciting sessions lined up on HCC. May 8th at #AIGhospitals @RoyAHep @karanbjmc93 @DrAshish_Kumar @docamitgs

PEI is common, frequently unrecognised – and not a 'pancreas-only problem.' New 'Mistakes in…' article unpacks the key clinical pitfalls: from overinterpreting faecal elastase results to insufficient nutritional assessment. Full article on Gutflix 🔗 bit.ly/4mDbeJF

◾ Evidence has shown that Tirzepatide with dual agonist activity to GLP1 and GIP receptors is effective at resolving steatohepatitis in patients with MASLD and fibrosis at 52 weeks...Now, how does Tirzepatide impact outcomes in patients with MASLD ➕ T2DM❓ ✍️ Halley et al. have conducted a short duration study that has promising results with significant improvement in liver stiffness, steatosis, A1c level and AST/ALT levels after 12 weeks. We highly recommend checking this short letter with study results ➡️ bit.ly/48MruCj 👏 Thank you to all authors @cnsrachel Callum James Riley Jill Johnson Maria Round Julian Yeh Sheeba Khan Alex Boyd Geoffrey Haydon Samiul Mostafa Philip Newsome @Drfattyliver @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @ulstergastro #GITwitter

New online! Lifespan approaches for the prevention and management of steatotic liver disease dlvr.it/TS3HmJ

The GOULASH trial has been published in @Gut_BMJ! Multicentric double-blind RCT in acute pancreatitis High versus gradually increasing energy in enteral nutrition to all comers with AP High energy was detrimental Congrats Katalin and Peter! gut.bmj.com/content/gutjnl…

From the Global Think-tank on Steatotic Liver Disease: "Global momentum builds as position statement on steatotic liver disease published in Nature Reviews Gastroenterology & Hepatology" sldthinktank.com/news/global-mo… Direct link: nature.com/articles/s4157… #SLDthinktank #ActOnNCDs

Harmonisation at what price? Our new Expert Opinion in @JHepatology asks whether the new ACLF consensus achieves unity through evidence — or through dilution. Definitions matter. Patients depend on them 👇 journal-of-hepatology.eu/action/showPdf… #ACLF @EASL @AASLD @APASLnews @LiverUcl @ef_clif

A question I keep sitting with: what do we do for patients with cirrhosis when the therapy we've been relying on shows limited efficacy beyond one indication and is raising antimicrobial resistance signals in an already vulnerable gut? Our Viewpoint in @TheLancet Gastroenterology & Hepatology looks at rifaximin — including the RED-C trial (@BauschHealth) and emerging resistance data — and asks whether it's time for stewardship-level scrutiny. @Alfasigma, who market it in Europe, should be part of this conversation too. But the bigger question is: where are the safe, effective gut microbiome therapies our cirrhosis patients actually need? There's promising work emerging — @EnteroBiotix in liver cirrhosis, @MaaTpharma, @VedantaBio, @Seres_Tx, @FerringPharma/@Rebiotix. And I should declare an interest: @YaqritLtd's Yaq-001 has shown reduced gut inflammation, improved microbiome composition and reduced AMR genes in cirrhosis trials — pivotal European trials coming in 2026. More at yaqrit.com. The biology is there. The unmet need is real. We need to accelerate. thelancet.com/journals/langa… authors.elsevier.com/a/1my6f8nByrKK… @vishalpatel @SaeedShoaie @LiverUcl @Inst_of_Liver @KingsCollegeLon

🔬 Review in JHEP Reports covering lifestyle, AOMs, and bariatric surgery across all fibrosis stages 📊 Semaglutide 2.4 mg in compensated MASH-cirrhosis (n=47, 48 wk): 34% MASH resolution, 11% fibrosis improvement 📉 Compare that to F2-F3 (ESSENCE): 62.9% MASH resolution, 36.8% fibrosis improvement 🟢 Bariatric surgery at 5 years (n=64): 84.4% MASH resolution, 50% fibrosis resolution 🫀 SPLENDOR: surgery in MASH-cirrhosis cut major liver outcomes (HR 0.28) and MACE (aHR 0.12) ⚠️ Portal hypertension, sarcopenia, and malnutrition complicate every intervention in ACLD The sickest patients have the fewest options. Phase 3 ESSENCE extension for cirrhosis (NCT07166528) is the trial to watch. 🏁 doi.org/10.1016/j.jhep…

Liver fibrosis is the main hallmark of chronic liver disease, progressing silently over decades and often remaining undetected. A new study assessed the prevalence of undiagnosed liver fibrosis and its relationship with metabolic factors or alcohol consumption: spkl.io/6016ANmW2

A new Annals #InTheClinic explores the inpatient management of patients with cirrhosis. bit.ly/4vrY8mu

🟣Management of obesity in advanced chronic liver disease 🔓#OpenAccess at 👉jhep-reports.eu/article/S2589-… #LiverX #LiverDisease #LiverHealth

Grateful and humbled to share that our study from PGI Chandigarh 🇮🇳has been published in BMJ Gut 🇬🇧 This milestone wouldn’t have been possible without the constant guidance, support, and mentorship of my respected teachers and guides. @HMandavdhare @drvishal82 @DrJimilShah

India has 9 income classes Poor - <₹5K: survival - ₹5–12K: basic needs - ₹12–20K: rent struggle Middle - ₹20–40K: just managing - ₹40–80K: EMI life - ₹80K–1.5L:“looks rich, feels broke” Rich - ₹1.5–4L: comfortable - ₹4–25L: wealth building - ₹25L+: generational wealth

IMF Growth Forecast 2026: 🇺🇸 US: 2.3% 🇩🇪 Germany: 0.8% 🇫🇷 France: 0.9% 🇮🇹 Italy: 0.5% 🇪🇸 Spain: 2.1% 🇬🇧 UK: 0.8% 🇯🇵 Japan:0.7% 🇨🇦 Canada: 1.5% 🇨🇳 China: 4.4% 🇮🇳 India: 6.5% 🇷🇺 Russia: 1.1% 🇧🇷 Brazil: 1.9% 🇲🇽 Mexico: 1.6% 🇸🇦 Saudi Arabia: 3.1% 🇳🇬 Nigeria: 4.1% 🇿🇦 South Africa: 1.0% imf.org/en/publication…

🆕Metabolic dysfunction-associated steatotic liver disease could affect nearly 1.8 billion people by 2050, according to new data from #GBDStudy 2023 thelancet.com/journals/langa… @IHME_UW #GITwitter #LiverTwitter #MedTwitter

The idea of #obesity as a disease is at the centre of one of the most controversial and polarising debates in modern medicine, with broad and far-reaching implications for people affected and the society as a whole thelancet.com/journals/landi… #FREE to read w/reg (also FREE)